We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana, a Zacks Rank #1 (Strong Buy), has gone from the most beaten-down name in managed care to one of the market's best performers in the span of a single year.
The company that investors abandoned over a collapse in its Medicare Advantage Star Ratings has spent 2026 methodically repairing the problem, and the evidence is now showing up in both the earnings estimates and the stock.
Shares have gained roughly 48% year to date and set a new 52-week high earlier this week, leaving both the Zacks Medical sector and the broader HMO group well behind. A stock that rallies this hard while analysts are still raising their numbers is precisely the combination we look for in a market leader.
Humana is part of the Zacks Medical – HMOs industry group, which currently ranks in the top 12% out of approximately 250 Zacks Ranked Industries. Because it is ranked in the top half of all Zacks Ranked Industries, we expect this group to outperform over the next 3 to 6 months.
Take note of the favorable characteristics for this group below. Stocks in this industry are projected to experience above-average earnings growth, which should serve as a powerful foundation to higher stock prices over time.
Image Source: Zacks Investment Research
Historical research studies suggest that approximately half of a stock's price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries outperforms the bottom 50% by a factor of more than 2 to 1.
It's no secret that investing in stocks that are part of leading industry groups can give us a leg up relative to the market. By focusing on leading stocks within the top 50% of Zacks Ranked Industries, we can dramatically improve our odds of success.
Company Description
Humana is one of the largest Medicare Advantage insurers in the United States. The company operates through two segments. Its Insurance segment offers Medicare Advantage, stand-alone Medicare Part D prescription drug plans and Medicaid coverage, while its CenterWell segment provides senior-focused primary care, home health and pharmacy services.
That combination makes Humana unusually concentrated in the Medicare population, which is both its greatest source of growth and the reason it suffered so badly when its quality scores slipped.
The Star Ratings story is the heart of this turnaround. Medicare pays quality bonuses to plans rated four stars or higher, and Humana's ratings deteriorated sharply in the 2025 cycle, creating a revenue headwind that has weighed on 2026 earnings. Management responded with an operational overhaul aimed at quality metrics, and the payoff arrived in October.
Based on final 2027 Star Ratings data from CMS, Humana posted a member-weighted rating of 4.17 — approaching the best in its history — and exceeded its goal of top-quartile results, defined as Stars revenue per member at least 10% above the median of Centene, CVS, Elevance, HCSC and UnitedHealth. Those ratings determine bonus payments in 2028, giving investors a clear line of sight on a meaningful tailwind.
CenterWell continues to build quietly underneath. Senior primary care added roughly 146,800 patients this year, a 30% increase that includes the MaxHealth acquisition, while Medicaid membership grew about 7% and now spans 13 states.
A Smaller Loss and a Higher Floor
Humana reported third-quarter results on November 6th that beat on both lines. The company posted an adjusted loss of $0.70 per share against the Zacks Consensus Estimate for a loss of $1.03, a surprise of roughly 32%, and it has now topped the consensus in each of the last four quarters. Revenue climbed about 26% to $41.2 billion, ahead of expectations near $40.9 billion.
The cost line drove the beat. The Insurance segment benefit ratio came in at 93.7%, better than management's guidance of slightly above 94%, and the consolidated adjusted operating cost ratio improved to 11.2% from 11.8% a year earlier. Medical cost trend is running at the low end of the expected 7% to 8% range for 2026, and management says individual Medicare Advantage pretax margin is on track to double this year excluding the Stars headwind.
Management raised its 2026 adjusted earnings floor to at least $9.50 per share from $9.00. Just as important for next year, the company now expects 2027 Medicare Advantage membership to grow, a reversal from its earlier flat-to-down view, with retention and new sales in the current enrollment period running ahead of plan.
Analysts have moved higher with management. The Zacks Consensus Estimate for 2026 stands at $9.52 per share, having climbed more than 4% over the past three months. The more striking figure is next year: the 2027 consensus sits at $17.26, which would represent growth of more than 81% on revenue of roughly $171.5 billion. Estimates rising for both the current year and the recovery year are the engine behind the Zacks Rank #1.
Image Source: Zacks Investment Research
Let's Get Technical
Humana (HUM - Free Report) shares have been in a persistent uptrend throughout 2026, trading above an upward-sloping 200-day (red line) moving average and carving out a steady series of higher highs and higher lows. A recent pullback presents an intriguing buying opportunity.
Image Source: StockCharts
Only stocks in genuinely owerful uptrends make this type of move and sustain it. This is the kind of name we want in the portfolio — one that is trending well and receiving positive earnings estimate revisions at the same time.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. As long as that trend remains intact and Humana continues to deliver earnings beats, the stock should continue its bullish run.
Bottom Line
Backed by a leading industry group, four straight earnings beats, a raised guidance floor and a Star Ratings recovery that sets up a multi-year earnings rebuild, it isn't difficult to see why this company is a compelling investment right now. Humana carries a Zacks Rank #1 (Strong Buy) driven by favorable estimate momentum, along with an 'A' Zacks VGM Style Score.
Robust fundamentals combined with a strong technical trend certainly justify adding shares to the mix. If you haven't already done so, be sure to put HUM on your watchlist.
Bull of the Day: Humana (HUM)
Humana, a Zacks Rank #1 (Strong Buy), has gone from the most beaten-down name in managed care to one of the market's best performers in the span of a single year.
The company that investors abandoned over a collapse in its Medicare Advantage Star Ratings has spent 2026 methodically repairing the problem, and the evidence is now showing up in both the earnings estimates and the stock.
Shares have gained roughly 48% year to date and set a new 52-week high earlier this week, leaving both the Zacks Medical sector and the broader HMO group well behind. A stock that rallies this hard while analysts are still raising their numbers is precisely the combination we look for in a market leader.
Humana is part of the Zacks Medical – HMOs industry group, which currently ranks in the top 12% out of approximately 250 Zacks Ranked Industries. Because it is ranked in the top half of all Zacks Ranked Industries, we expect this group to outperform over the next 3 to 6 months.
Take note of the favorable characteristics for this group below. Stocks in this industry are projected to experience above-average earnings growth, which should serve as a powerful foundation to higher stock prices over time.
Image Source: Zacks Investment Research
Historical research studies suggest that approximately half of a stock's price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries outperforms the bottom 50% by a factor of more than 2 to 1.
It's no secret that investing in stocks that are part of leading industry groups can give us a leg up relative to the market. By focusing on leading stocks within the top 50% of Zacks Ranked Industries, we can dramatically improve our odds of success.
Company Description
Humana is one of the largest Medicare Advantage insurers in the United States. The company operates through two segments. Its Insurance segment offers Medicare Advantage, stand-alone Medicare Part D prescription drug plans and Medicaid coverage, while its CenterWell segment provides senior-focused primary care, home health and pharmacy services.
That combination makes Humana unusually concentrated in the Medicare population, which is both its greatest source of growth and the reason it suffered so badly when its quality scores slipped.
The Star Ratings story is the heart of this turnaround. Medicare pays quality bonuses to plans rated four stars or higher, and Humana's ratings deteriorated sharply in the 2025 cycle, creating a revenue headwind that has weighed on 2026 earnings. Management responded with an operational overhaul aimed at quality metrics, and the payoff arrived in October.
Based on final 2027 Star Ratings data from CMS, Humana posted a member-weighted rating of 4.17 — approaching the best in its history — and exceeded its goal of top-quartile results, defined as Stars revenue per member at least 10% above the median of Centene, CVS, Elevance, HCSC and UnitedHealth. Those ratings determine bonus payments in 2028, giving investors a clear line of sight on a meaningful tailwind.
CenterWell continues to build quietly underneath. Senior primary care added roughly 146,800 patients this year, a 30% increase that includes the MaxHealth acquisition, while Medicaid membership grew about 7% and now spans 13 states.
A Smaller Loss and a Higher Floor
Humana reported third-quarter results on November 6th that beat on both lines. The company posted an adjusted loss of $0.70 per share against the Zacks Consensus Estimate for a loss of $1.03, a surprise of roughly 32%, and it has now topped the consensus in each of the last four quarters. Revenue climbed about 26% to $41.2 billion, ahead of expectations near $40.9 billion.
The cost line drove the beat. The Insurance segment benefit ratio came in at 93.7%, better than management's guidance of slightly above 94%, and the consolidated adjusted operating cost ratio improved to 11.2% from 11.8% a year earlier. Medical cost trend is running at the low end of the expected 7% to 8% range for 2026, and management says individual Medicare Advantage pretax margin is on track to double this year excluding the Stars headwind.
Management raised its 2026 adjusted earnings floor to at least $9.50 per share from $9.00. Just as important for next year, the company now expects 2027 Medicare Advantage membership to grow, a reversal from its earlier flat-to-down view, with retention and new sales in the current enrollment period running ahead of plan.
Analysts have moved higher with management. The Zacks Consensus Estimate for 2026 stands at $9.52 per share, having climbed more than 4% over the past three months. The more striking figure is next year: the 2027 consensus sits at $17.26, which would represent growth of more than 81% on revenue of roughly $171.5 billion. Estimates rising for both the current year and the recovery year are the engine behind the Zacks Rank #1.
Image Source: Zacks Investment Research
Let's Get Technical
Humana (HUM - Free Report) shares have been in a persistent uptrend throughout 2026, trading above an upward-sloping 200-day (red line) moving average and carving out a steady series of higher highs and higher lows. A recent pullback presents an intriguing buying opportunity.
Image Source: StockCharts
Only stocks in genuinely owerful uptrends make this type of move and sustain it. This is the kind of name we want in the portfolio — one that is trending well and receiving positive earnings estimate revisions at the same time.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. As long as that trend remains intact and Humana continues to deliver earnings beats, the stock should continue its bullish run.
Bottom Line
Backed by a leading industry group, four straight earnings beats, a raised guidance floor and a Star Ratings recovery that sets up a multi-year earnings rebuild, it isn't difficult to see why this company is a compelling investment right now. Humana carries a Zacks Rank #1 (Strong Buy) driven by favorable estimate momentum, along with an 'A' Zacks VGM Style Score.
Robust fundamentals combined with a strong technical trend certainly justify adding shares to the mix. If you haven't already done so, be sure to put HUM on your watchlist.